SecBot SecBot
Biotech Drug Report Generated Oct 25, 2026

XYOSTED

HALO·Halozyme Therapeutics, Inc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and marketed (FDA-approved since 2019)
Why 3/10
XYOSTED is an already-approved, commercial-stage drug with no pending PDUFA date or pivotal readout in the next ~12 months. It represents a small portion of Halozyme's overall revenue; the company's primary value driver is its ENHANZE drug-delivery platform royalties from partners. There is no hard, dated binary catalyst for this specific drug.
Actionable Insight NEUTRAL

XYOSTED itself presents no near-term binary catalyst. For HALO investors, the focus should be on ENHANZE royalty revenue growth (driven by partners like argenx's VYVGART Hytrulo and J&J's DARZALEX FASPRO) and the Q3 2026 earnings report on November 5, 2026. The stock trades above its mean analyst target, suggesting limited near-term upside based on consensus estimates.

Price Chart

Loading chart...

Executive Summary

XYOSTED (testosterone enanthate) is an FDA-approved, once-weekly subcutaneous auto-injector for testosterone replacement therapy in adult males with hypogonadism. It was originally developed and brought to market by Antares Pharma, which Halozyme Therapeutics acquired in 2022 for approximately $960 million. XYOSTED is a commercial-stage product with no pending regulatory catalysts. For Halozyme, it is a secondary asset behind the company's core ENHANZE drug-delivery technology platform, which generates the majority of value through royalty partnerships with large pharma (J&J, Roche, argenx, Takeda). As of late October 2026, HALO trades at ~$125.63 with a consensus Buy rating and mean price target of ~$109.

How It Works

XYOSTED is a once-weekly subcutaneous (under-the-skin) auto-injector that delivers testosterone enanthate, a replacement therapy for adult males whose bodies do not produce enough natural testosterone (hypogonadism). It replaces testosterone at normal levels to restore growth, development, and function of male sex organs and secondary sexual characteristics.

Trial Status

XYOSTED was FDA-approved in 2019 (originally by Antares Pharma). It is a commercially marketed product with no ongoing pivotal clinical trials for a new indication. Halozyme acquired XYOSTED through its $960M acquisition of Antares Pharma in 2022.

The Two-Sided Case

▲ Bull Case3
Steady commercial revenue from an established, FDA-approved product with a clear use case (testosterone replacement) and a convenient auto-injector delivery format.
Part of a diversified product portfolio at Halozyme that includes higher-growth ENHANZE-royalty assets, providing revenue stability.
Acquired at a reasonable valuation ($960M for Antares Pharma including XYOSTED and other assets), and adds to Halozyme's self-injection device capabilities.
▼ Bear Case4
Competition in the testosterone replacement market is intense, AbbVie's AndroGel, Endo's Aveed, and various generic/other topical and injectable testosterone products limit XYOSTED's market share and pricing power.
As a relatively small product within Halozyme's portfolio, XYOSTED's performance has limited impact on HALO stock price.
Testosterone replacement therapy faces ongoing regulatory scrutiny regarding cardiovascular safety and appropriate prescribing practices, which could impact the category.
Generic competition risk over time as patents expire.

Upcoming Catalysts

  • No upcoming FDA/Pivotal binary catalysts for XYOSTED specifically, it is a mature, approved product. Halozyme's key near-term catalyst is Q3 2026 earnings on November 5, 2026, which will include product revenue updates across the portfolio including XYOSTED.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Halozyme Therapeutics, Inc. PRESS-RELEASE HALO ·Originating report

Sources · 3

Hover a chip for the title
1 sec.gov2 sec.gov3 sec.gov